Vinva Investment Management Ltd grew its holdings in Danaher Co. (NYSE:DHR - Free Report) by 5.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,569 shares of the conglomerate's stock after acquiring an additional 1,637 shares during the period. Vinva Investment Management Ltd's holdings in Danaher were worth $7,479,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in DHR. FMR LLC increased its stake in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate's stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Danaher by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate's stock valued at $1,971,609,000 after buying an additional 441,012 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate's stock worth $1,417,342,000 after buying an additional 148,251 shares during the period. Fisher Asset Management LLC lifted its position in shares of Danaher by 0.6% during the 4th quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate's stock valued at $1,051,097,000 after buying an additional 26,305 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Danaher by 3.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate's stock valued at $933,524,000 after acquiring an additional 135,047 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.
Analysts Set New Price Targets
DHR has been the topic of several recent analyst reports. Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They set a "buy" rating and a $275.00 price objective on the stock. Jefferies Financial Group lowered their price objective on Danaher from $285.00 to $260.00 and set a "buy" rating on the stock in a report on Wednesday, January 29th. Royal Bank of Canada reiterated an "outperform" rating and set a $277.00 price objective (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. StockNews.com downgraded Danaher from a "buy" rating to a "hold" rating in a research report on Saturday, December 14th. Finally, Scotiabank began coverage on Danaher in a research note on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 price objective for the company. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $278.24.
Get Our Latest Stock Analysis on Danaher
Danaher Trading Up 0.7 %
DHR stock traded up $1.38 during mid-day trading on Friday, hitting $211.63. 6,383,342 shares of the company were exchanged, compared to its average volume of 3,016,750. The business has a fifty day simple moving average of $217.46 and a 200-day simple moving average of $238.68. The firm has a market capitalization of $151.26 billion, a P/E ratio of 40.08, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the firm posted $2.09 earnings per share. On average, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.60%. This is a boost from Danaher's previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher's dividend payout ratio (DPR) is 24.24%.
Insider Buying and Selling at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company's stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 10.90% of the stock is currently owned by corporate insiders.
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
